BTIG analyst Ryan Zimmerman maintained a Buy rating on Organogenesis Holdings (ORGO) yesterday and set a price target of $10.00. The company’s shares closed last Monday at $4.15.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 11.9% and a 55.1% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Staar Surgical Company, and Zimmer Biomet Holdings.
Currently, the analyst consensus on Organogenesis Holdings is a Strong Buy with an average price target of $8.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.34 and a one-year low of $2.47. Currently, Organogenesis Holdings has an average volume of 145.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
Read More on ORGO:
